Our goal is
to detect pancreatic cancer in its earliest stages.
Within this decade, pancreatic cancer is expected to be the second leading cause of cancer mortality in the United States. However, it’s been shown that diagnosis at an early stage, when patients have better treatment options, has the potential to increase survival rates by more than ten times. ClearNote Health is working to address the unmet need with its introduction of the Avantect Pancreatic Cancer Test.
Pancreatic cancer is the third leading cause of cancer-related death and is predicted to be the second most common cause by 2030.
deaths in the US in 2025
adults diagnosed in 2025
Pancreatic cancer diagnosed at its earliest stage can improve survival
Until now, limited early detection technologies for pancreatic cancer have prevented patients from seeking treatment in early stages when more effective therapies are still possible. The stage of pancreatic cancer at diagnosis has a significant impact on survival.
Addressing an Unmet Medical Need
Prioritizing high-risk patients
The Avantect Pancreatic Cancer Test is a simple DNA-based blood test is designed to make earlier diagnosis possible for patients at high risk for pancreatic cancer. It is therefore essential to identify patients at high risk for pancreatic cancer who would benefit from testing.
